Fig. 1.

OS in Japanese patients with a tumor PD-L1 expression ≥ 1%, b tumor PD-L1 expression < 1%, and c tumor PD-L1 expression ≥ 1% and < 1%. ^a95% CIs, 30%–60% (nivolumab plus ipilimumab) and 21%–47% (chemotherapy). ^b95% CIs, 18%–54% (nivolumab plus ipilimumab) and 7%–35% (chemotherapy). ^c95% CIs, 30%–54% (nivolumab plus ipilimumab) and 18%–39% (chemotherapy). CI confidence interval; HR hazard ratio; OS overall survival; PD-L1 programmed death ligand 1